Responsible Institution: China Association for Science and Technology
Sponsored by: The Chinese Pharmacological Society
Editor-in-Chief: HUANG Zhili
ISSN 1009-2501
CN 34-1206/R
XIAO Hui-lai. Written main contents of six sections of labeling for prescription drug and cautions[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(12): 1437-1440.
[1] 国家食品药品监督管理局. 药品说明书和标签管理规定[EB/OL]. http://www.sfda.gov.cn/WS01/CL0053/24522.html. ,2006-03-15. [2] 国家食品药品监督管理局. 化学药品和治疗用生物制品说明书规范细则[EB/OL]. http://www.sfda.gov.cn/WS01/CL0055/10528.html. ,2006-05-10. [3] 《化学药品、生物制品说明书指导原则》课题研究组.化学药品、生物制品说明书指导原则(第二稿)[EB/OL]. http://www.cde.org.cn/zdyz.do?method=largePage&id=44. 2004-03-01. [4] Department of health and human services U.S. Food and drug Administration. Section 201.57. Specific requirements on content and format of labeling for human prescription drug and biological products. Part 201 Labeling Title 21 Code of Federal Regulations USA [EB/OL].http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.56.2010-04-01. [5] FDA.Guidance for Industry Labeling for Human rescription Drug and Biological Products -Implementing the New Content and Format Requirements [EB/OL].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075082.pdf. 2006-01-18. [6] FDA. Guidance for Industry Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products- Content Format February 2009. [EB/OL].http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065010.htm.,2009-03-03.